Viking Therapeutics, Inc. (VKTX) Financial Statements (2024 and earlier)
Company Profile
Business Address |
9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO, CA 92121 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 155,485 | 202,103 | 248,386 | 275,638 | 301,520 | 20,576 | |||
Cash and cash equivalents | 36,632 | 26,371 | 29,117 | 8,377 | 24,779 | 8,988 | |||
Short-term investments | 118,853 | 175,732 | 219,269 | 267,261 | 276,741 | 11,587 | |||
Other undisclosed current assets | 11,555 | 8,425 | 7,718 | 7,863 | 613 | 1,276 | |||
Total current assets: | 167,040 | 210,528 | 256,104 | 283,501 | 302,133 | 21,852 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 1,418 | 25 | 321 | 598 | ✕ | ✕ | |||
Deposits noncurrent assets | 33 | 33 | 29 | 29 | 29 | ||||
Other undisclosed noncurrent assets | 38 | 76 | 48 | 128 | 150 | 270 | |||
Total noncurrent assets: | 1,489 | 134 | 398 | 755 | 179 | 270 | |||
TOTAL ASSETS: | 168,529 | 210,662 | 256,502 | 284,256 | 302,312 | 22,121 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 21,643 | 8,749 | 11,799 | 6,475 | 4,550 | 3,808 | |||
Interest and dividends payable | ✕ | ✕ | 22 | ||||||
Accounts payable | 8,529 | 1,444 | 3,988 | 2,431 | 959 | 1,530 | |||
Accrued liabilities | 13,114 | 7,305 | 7,811 | 4,044 | 3,591 | 2,257 | |||
Debt | 302 | 3,451 | |||||||
Other undisclosed current liabilities | 304 | 29 | 330 | 1,398 | |||||
Total current liabilities: | 21,947 | 8,778 | 12,129 | 6,777 | 4,550 | 8,657 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation: | 29 | 360 | |||||||
Liabilities, other than long-term debt | 1,260 | 12 | |||||||
Deferred rent credit | 12 | ✕ | |||||||
Operating lease, liability | 1,260 | 29 | 360 | ✕ | ✕ | ||||
Other undisclosed noncurrent liabilities | (29) | ||||||||
Total noncurrent liabilities: | 1,260 | 29 | 360 | 12 | |||||
Total liabilities: | 23,207 | 8,778 | 12,158 | 7,137 | 4,562 | 8,657 | |||
Equity | |||||||||
Equity, attributable to parent | 145,322 | 201,884 | 244,344 | 277,119 | 297,750 | 13,465 | |||
Common stock | 1 | 1 | 1 | 1 | 1 | 0 | |||
Treasury stock, value | (6,795) | ||||||||
Additional paid in capital | 445,267 | 425,614 | 412,589 | 405,803 | 401,090 | 94,339 | |||
Accumulated other comprehensive income (loss) | (1,102) | (549) | (54) | 12 | (423) | (20) | |||
Accumulated deficit | (292,049) | (223,182) | (168,192) | (128,697) | (102,918) | (80,855) | |||
Total equity: | 145,322 | 201,884 | 244,344 | 277,119 | 297,750 | 13,465 | |||
TOTAL LIABILITIES AND EQUITY: | 168,529 | 210,662 | 256,502 | 284,256 | 302,312 | 22,121 |
Income Statement (P&L) ($ in thousands)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 40 | 4 | ||||||
Gain (loss) on disposition of assets for financial service operations | (42) | 40 | 4 | (12) | ✕ | |||
Gross profit: | 40 | 4 | ||||||
Operating expenses | (70,355) | (55,682) | (42,662) | (32,687) | (26,161) | (19,070) | ||
Other undisclosed operating income (loss) | 42 | (40) | (4) | 12 | ||||
Operating loss: | (70,355) | (55,682) | (42,662) | (32,687) | (26,161) | (19,070) | ||
Nonoperating income (expense) | 271 | (3,207) | (641) | 6,431 | 4,025 | (1,507) | ||
Investment income, nonoperating | (1,217) | (3,906) | (3,808) | (477) | (73) | |||
Other nonoperating income (expense) | 1,488 | 692 | 3,167 | 6,908 | 4,098 | (1,507) | ||
Loss from continuing operations before income taxes: | (70,084) | (58,889) | (43,303) | (26,256) | (22,136) | (20,578) | ||
Income tax expense (benefit) | (1) | (2) | 12,724 | 7,833 | 8,984 | |||
Other undisclosed loss from continuing operations | ||||||||
Loss from continuing operations: | (70,085) | (58,891) | (30,579) | (18,423) | (13,152) | (20,578) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | (58,891) | (30,579) | (18,423) | (13,152) | (20,578) | |
Other undisclosed net income (loss) | 1,218 | 3,901 | (8,916) | (7,356) | (8,911) | |||
Net loss available to common stockholders, diluted: | (68,867) | (54,990) | (39,495) | (25,779) | (22,063) | (20,578) |
Comprehensive Income ($ in thousands)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (68,867) | (54,990) | (39,495) | (25,779) | (22,063) | (20,578) | ||
Comprehensive loss: | (68,867) | (54,990) | (39,495) | (25,779) | (22,063) | (20,578) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (553) | (495) | (66) | 435 | (403) | (13) | ||
Comprehensive loss, net of tax, attributable to parent: | (69,420) | (55,485) | (39,561) | (25,344) | (22,466) | (20,591) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.